Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens.

Pierre Merville1

  • 1Department of Nephrology, Centre Hospitalier Universitaire (CHU) Pellegrin, Bordeaux, France. pierre.merville@chu-bordeaux.fr

Drugs
|March 8, 2005
PubMed
Summary

Chronic renal allograft dysfunction (CRAD) is a major cause of kidney transplant failure. Optimizing immunosuppression by switching from calcineurin inhibitors (CNIs) may improve long-term graft survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and factors associated with Herpes Zoster infection in kidney transplant recipients, a recent epidemiological study.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Interactions Between Immunosuppressive Regimens and Cytomegalovirus Infection After Solid-Organ Transplantation.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Adoptive γδ T cell therapy controls cytomegalovirus infection in preclinical transplantation models.

Nature communications·2026
Same author

Spiroplasma infection complicated by macrophage activation syndrome and fulminant hepatitis in a kidney transplant recipient.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Effector-Memory γδ T Lymphocytes Predict CMV Disease After the Withdrawal of Prophylaxis in Kidney Transplant Recipients.

Transplant international : official journal of the European Society for Organ Transplantation·2025
Same author

Thrombocytopenia following kidney transplantation: a frequent, underestimated and potentially severe complication.

Frontiers in immunology·2025

Area of Science:

  • Nephrology
  • Transplantation Immunology
  • Immunosuppression Therapy

Background:

  • Kidney transplantation offers superior survival and quality of life for end-stage renal disease patients.
  • Chronic renal allograft dysfunction (CRAD) is the primary cause of late kidney graft failure, characterized by progressive dysfunction and specific biopsy findings.
  • Calcineurin inhibitors (CNIs) are frequently associated with graft injury beyond the first year post-transplantation.

Purpose of the Study:

  • To explore the complex pathophysiology of CRAD.
  • To discuss the evolving nature of CRAD and the need for dynamic immunosuppressive strategies.
  • To propose a paradigm shift in immunosuppression for kidney transplant recipients.

Main Methods:

  • Review of existing literature on CRAD pathophysiology and management.

Related Experiment Videos

  • Analysis of factors contributing to CRAD, including alloantigen-dependent and independent elements.
  • Discussion of current and emerging immunosuppressive agents and treatment strategies.

    • Main Results:

    • CRAD is multifactorial, involving both immune and non-immune factors.
    • Early CNI use is common, but long-term nephrotoxicity contributes to CRAD.
    • Individualized immunosuppression, potentially involving CNI withdrawal, is suggested.

    Conclusions:

    • CRAD management requires tailored immunosuppressive regimens based on the transplant phase.
    • A strategy of initial CNI-based immunosuppression followed by conversion to a CNI-free regimen may mitigate long-term nephrotoxicity.
    • Further large-scale trials are needed to define CRAD endpoints and optimal therapeutic strategies.